(ORTI-B) Ortivus ser. - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000123085
ORTI-B: Patient Monitors, Electronic Health Records, Data Sharing Platforms
Ortivus AB (publ), a leader in healthcare IT, specializes in developing innovative medical technology and e-health solutions tailored for emergency medical services. Their flagship MobiMed product line includes MobiMed Monitor, which enables real-time sharing of vital signs and ECG data for remote patient monitoring. MobiMed ePR is an electronic patient record system that digitizes patient data, enhancing accessibility and reducing errors. MobiMed enRoute features GPS navigation to optimize ambulance response times, while FleetCtrl manages fleet operations, ensuring efficient deployment and maintenance. MobiMed Life focuses on heart safety solutions, potentially including defibrillators for emergency response. Beyond technology, Ortivus provides essential healthcare services, including ambulance operations and primary care, underscoring their comprehensive approach to healthcare solutions.
Headquartered in Stockholm since 1985, Ortivus serves both Swedish and international markets. Their commitment to integrating technology with healthcare has established them as a key player in the industry. For more information, visit their website at https://www.ortivus.com.
Exchange: ST
Type: common stock
Country Origin: Sweden
GICS Sub Industry: Life Sciences Tools & Services
Last Price: 1.64
SMA 20: 1.68
SMA 50: 1.65
SMA 200: 1.87
ATR: 0.12
P/E: 0.00
P/E Forward: 0.00
P/B: 10.62
P/S: 0.93
RoE: 344.17
3-Month Forecast: Ortivus AB ser. B (ST:ORTI-B) is expected to enter a consolidation phase, with the stock price potentially trading sideways near the SMA50 level of 1.65. The average true range (ATR) of 0.12 indicates moderate volatility, suggesting price fluctuations within a narrow range. The stock is currently below its SMA20 and SMA50 but above the SMA200, signaling a neutral trend with possible breaks above or below key resistance levels. The high price-to-book (P/B) ratio of 10.62 and the absence of a P/E ratio raise concerns about valuation and profitability. However, the low price-to-sales (P/S) ratio of 0.93 may attract value investors. The extremely high return on equity (RoE) of 344.17 warrants caution, possibly indicating high leverage or accounting factors. Investors should monitor earnings reports and industry developments for clarity on the companys growth prospects.
Additional Sources for ORTI-B Stock
ORTI-B Stock Overview
| Market Cap in USD | 7m |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
ORTI-B Stock Ratings
| Growth Rating | -76.9 |
| Fundamental | -48.2 |
| Dividend Rating | 0.0 |
| Rel. Strength | -50.1 |
| Analysts | - |
| Fair Price Momentum | 0.99 SEK |
| Fair Price DCF | - |
ORTI-B Dividends
No Dividends PaidORTI-B Growth Ratios
| Growth Correlation 3m | -55.3% |
| Growth Correlation 12m | -70% |
| Growth Correlation 5y | -70.4% |
| CAGR 5y | -19.48% |
| CAGR/Max DD 5y | -0.23 |
| Sharpe Ratio 12m | -0.08 |
| Alpha | -54.72 |
| Beta | -0.006 |
| Volatility | 59.20% |
| Current Volume | 11.8k |
| Average Volume 20d | 3.9k |
As of April 26, 2025, the stock is trading at SEK 1.30 with a total of 11,779 shares traded.
Over the past week, the price has changed by -11.30%, over one month by -25.70%, over three months by -23.52% and over the past year by -49.99%.
Probably not. Based on ValueRay Fundamental Analyses, Ortivus ser. (ST:ORTI-B) is currently (April 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -48.21 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ORTI-B as of April 2025 is 0.99. This means that ORTI-B is currently overvalued and has a potential downside of -23.85%.
Ortivus ser. has no consensus analysts rating.
According to ValueRays Forecast Model, ORTI-B Ortivus ser. will be worth about 1.1 in April 2026. The stock is currently trading at 1.30. This means that the stock has a potential downside of -17.69%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1.1 | -17.7% |